Table 2. Randomized controlled trials of GLP-1-RAs reporting data on amputation and the course of PAOD^*.

Trial	Drug	GLP-1-RAs	Control	Hazard ratio [95% CI]
		n = Number with PAOD (%) A = Number of amputations (%)	n = Number with PAOD (%) A = Number of amputations (%)
Badjatiya et al. 2019 (37)	Exenatide	n = 1400 (19.0) A = 70 (5.0)	n = 1400 (18.9) A = 69 (4.9)	0.99 [0.71; 1.38] 0.96 [0.66; 1.41]
		n = Acute or chronic limb ischemia requiring hospitalization M = number of MALEs (%)
Bonaca et al. 2025 (31)	Semaglutide	n = 396 M = 6 (1.5)	n = 396 M = 5 (1.3)	1.21 [0.36; 4.20]
		n = Indicated peripheral revascularization per trial arm (%)		For peripheral revascularization
Holman et al. 2017 (e5)	Exenatide	n = 117 (1.9)	n = 157 (2.1)	n.a.
Marso et al. 2016 (e6)	Semaglutide	n = 16 (1)	n = 25 (1.5)	0.64 [0.34; 1.20]

^*For ref. (37), the table reports the proportion of patients with PAOD at trial enrolment (where available from the publication) and the amputation rate over the course of the trial; for ref. (31), the occurrence of acute or chronic limb ischemia requiring hospitalization; and for refs. (e5, e6), the need for peripheral revascularization

GLP, glucagon-like peptide-1-receptor agonists; PAOD, peripheral arterial occlusive disease; MALE, major adverse limb events; n.a., not available; CI, confidence interval